Senhwa Biosciences, a clinical-stage biopharmaceutical company based in Taiwan, has entered a partnership with a global investment group to accelerate its artificial intelligence-related drug development. According to an April 14 report, Senhwa Biosciences has signed a Memorandum of Understanding (MOU)…
Related Posts
Bitmine ramps up Ether buys, pushes holdings toward 5% of total supply
While others refrain from boosting their Ether holdings, Bitmine’s latest purchase gives it ownership of about 4% of…
Analyst predicts $52k Bitcoin amid declining whale activity
Bitcoin (BTC) has gained bullish momentum amid declining whale activity while an analyst expects a downfall to the…
Crypto checks in: Ripple, Circle and BitGo want a piece of traditional banking
Kraken seeks an imminent launch of debit and credit cards while Ripple, Circle, and BitGo are applying for…